Blanch-Rubió, JosepSoldevila-Domenech, NataliaTío, LauraLlorente Onaindia, JoneCiria Recasens, ManuelPolino, LucianoGurt, AlbaTorre Fornell, Rafael de laMaldonado, Rafael, 1961-Monfort, JordiThe Covidmar Study Group2020-12-182020-12-182020Blanch-Rubió J, Soldevila-Domenech N, Tío L, Llorente-Onaindia J, Ciria-Recasens M, Polino L, Gurt A, de la Torre R, Maldonado R, Monfort J, Group TCS. Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions. Aging (Albany NY). 2020; 12(20):19923-37. DOI: 10.18632/aging.1041171945-4589http://hdl.handle.net/10230/46093Coronavirus disease 19 (COVID-19) is currently a global pandemic that affects patients with other pathologies. Here, we investigated the influence of treatments for osteoporosis and other non-inflammatory rheumatic conditions, such as osteoarthritis and fibromyalgia, on COVID-19 incidence. To this end, we conducted a cross-sectional study of 2,102 patients being treated at the Rheumatology Service of Hospital del Mar (Barcelona, Spain). In our cohort, COVID-19 cumulative incidence from March 1 to May 3, 2020 was compared to population estimates for the same city. We used Poisson regression models to determine the adjusted relative risk ratios for COVID-19 associated with different treatments and comorbidities. Denosumab, zoledronate and calcium were negatively associated with COVID-19 incidence. Some analgesics, particularly pregabalin and most of the studied antidepressants, were positively associated with COVID-19 incidence, whereas duloxetine presented a negative association. Oral bisphosphonates, vitamin D, thiazide diuretics, anti-hypertensive drugs and chronic non-steroidal anti-inflammatory drugs had no effect on COVID-19 incidence in the studied population. Our results provide novel evidence to support the maintenance of the main anti-osteoporosis treatments in COVID-19 patients, which may be of particular relevance to elderly patients affected by the SARS-CoV-2 pandemic.application/pdfeng© 2020 Blanch-Rubió et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.info:eu-repo/semantics/articlehttp://dx.doi.org/10.18632/aging.104117COVID-19Anti-resorptive drugsCalciumDenosumabVitamin DZoledronateinfo:eu-repo/semantics/openAccess